- Home
- ZENV vs STRO Comparison
ZENV vs STRO Comparison
Compare ZENV & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- STRO
- Stock Information
- Founded
- ZENV 2005
- STRO 2003
- Country
- ZENV Brazil
- STRO United States
- Employees
- ZENV N/A
- STRO N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- STRO Health Care
- Exchange
- ZENV Nasdaq
- STRO Nasdaq
- Market Cap
- ZENV 79.7M
- STRO 76.5M
- IPO Year
- ZENV 2021
- STRO 2018
- Fundamental
- Price
- ZENV $1.43
- STRO $0.86
- Analyst Decision
- ZENV
- STRO Hold
- Analyst Count
- ZENV 0
- STRO 7
- Target Price
- ZENV N/A
- STRO $1.97
- AVG Volume (30 Days)
- ZENV 104.7K
- STRO 436.1K
- Earning Date
- ZENV 11-17-2025
- STRO 11-12-2025
- Dividend Yield
- ZENV N/A
- STRO N/A
- EPS Growth
- ZENV N/A
- STRO N/A
- EPS
- ZENV N/A
- STRO N/A
- Revenue
- ZENV $201,426,369.00
- STRO $104,473,000.00
- Revenue This Year
- ZENV $6.49
- STRO $65.48
- Revenue Next Year
- ZENV $3.82
- STRO N/A
- P/E Ratio
- ZENV N/A
- STRO N/A
- Revenue Growth
- ZENV 24.80
- STRO N/A
- 52 Week Low
- ZENV $1.02
- STRO $0.52
- 52 Week High
- ZENV $3.03
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- ZENV 54.00
- STRO 45.34
- Support Level
- ZENV $1.26
- STRO $0.84
- Resistance Level
- ZENV $1.48
- STRO $0.95
- Average True Range (ATR)
- ZENV 0.08
- STRO 0.06
- MACD
- ZENV 0.02
- STRO -0.01
- Stochastic Oscillator
- ZENV 90.91
- STRO 19.04
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.